Sarah Onuora

List of Publications by Year
in descending order

168 papers	352 citations	1162367 8 h-index	1372195 10 g-index
173 all docs	173 docs citations	173 times ranked	758 citing authors

#	Article	IF	Citations
1	Cartilage matrix stiffness regulates chondrocyte metabolism and OA pathogenesis. Nature Reviews Rheumatology, 2015, 11, 504-504.	3.5	13
2	Vagus nerve stimulation reduces RA severity in patients. Nature Reviews Rheumatology, 2016, 12, 500-500.	3.5	13
3	Molecular imaging detects activated macrophages. Nature Reviews Rheumatology, 2016, 12, 313-313.	3.5	11
4	Wnt inhibitor shows potential as a DMOAD. Nature Reviews Rheumatology, 2017, 13, 634-634.	3.5	11
5	Could glucose metabolism be a sweet target for RA therapy?. Nature Reviews Rheumatology, 2016, 12, 131-131.	3.5	10
6	Targeting Rac1 via microparticle-based drug delivery system protects OA cartilage in vivo. Nature Reviews Rheumatology, 2014, 10, 1-1.	3.5	8
7	Targeting myostatin could prevent bone destruction in inflammatory arthritis. Nature Reviews Rheumatology, 2015, 11, 504-504.	3.5	8
8	Adipocyteâ€“myofibroblast transition: linking intradermal fat loss to skin fibrosis in SSc. Nature Reviews Rheumatology, 2015, 11, 63-63.	3.5	8
9	PBMCs stimulate chondrocyte migration and cartilage repair. Nature Reviews Rheumatology, 2015, 11, 563-563.	3.5	8
10	Gene therapy counteracts bone loss in osteoporosis. Nature Reviews Rheumatology, 2019, 15, 513-513.	3.5	8
11	Sprifermin shows cartilage-protective effects in knee OA. Nature Reviews Rheumatology, 2014, 10, 322-322.	3.5	7
12	UCMA links cartilage and bone in OA. Nature Reviews Rheumatology, 2017, 13, 130-130.	3.5	7
13	Anti-TNF kills the macrophage response. Nature Reviews Rheumatology, 2018, 14, 64-64.	3.5	7
14	Chondrocyte clock maintains cartilage tissue. Nature Reviews Rheumatology, 2016, 12, 71-71.	3.5	6
15	Hippo signalling influences T cell fate. Nature Reviews Rheumatology, 2017, 13, 389-389.	3.5	6
16	Sarilumab more effective than adalimumab. Nature Reviews Rheumatology, 2017, 13, 2-2.	3.5	6
17	RF levels predict RA risk in the general population. Nature Reviews Rheumatology, 2012, 8, 562-562.	3.5	5
18	IFNÎ³ signals control germinal centre formation. Nature Reviews Rheumatology, 2016, 12, 312-312.	3.5	5

#	Article	IF	Citations
19	Genetic variation affects IL-6 response in synovial fibroblasts. Nature Reviews Rheumatology, 2016, 12, 2-2.	3.5	5
20	IL-37 linked to gout pathogenesis and treatment. Nature Reviews Rheumatology, 2020, 16, 250-250.	3.5	5
21	How bad is obesity for RA?. Nature Reviews Rheumatology, 2012, 8, 306-306.	3.5	4
22	Autophagy is central to joint destruction in arthritis. Nature Reviews Rheumatology, 2012, 8, 633-633.	3.5	4
23	Can tofacitinib be used as first-line monotherapy for RA?. Nature Reviews Rheumatology, 2014, 10, 443-443.	3.5	4
24	Blood coagulation factor drives arthritis pathogenesis. Nature Reviews Rheumatology, 2014, 10, 700-700.	3.5	4
25	Antibody against CSF-1 receptor protects bone and cartilage. Nature Reviews Rheumatology, 2014, 10, 260-260.	3.5	4
26	Epsteinâ€“Barr virus in SjÃ¶gren's syndrome salivary glands drives local autoimmunity. Nature Reviews Rheumatology, 2014, 10, 384-384.	3.5	4
27	Novel NFÎºB inhibitor associated with RA severity. Nature Reviews Rheumatology, 2015, 11, 684-684.	3.5	4
28	Epratuzumab not effective in phase III trials. Nature Reviews Rheumatology, 2016, 12, 622-622.	3.5	4
29	Human gut bacteria induce TH17 cells. Nature Reviews Rheumatology, 2017, 13, 2-2.	3.5	4
30	MIF drives inflammation and bone formation in AS. Nature Reviews Rheumatology, 2017, 13, 451-451.	3.5	4
31	Anti-NXP2 antibodies associated with severe JDM. Nature Reviews Rheumatology, 2018, 14, 248-248.	3.5	4
32	Novel cytokine, IL-41, linked with PsA. Nature Reviews Rheumatology, 2019, 15, 636-636.	3.5	4
33	Synovial fibroblast expansion in RA is driven by Notch signalling. Nature Reviews Rheumatology, 2020, 16, 349-349.	3.5	4
34	Tofacitinib alleviates pain in RA, PsA and AS. Nature Reviews Rheumatology, 2020, 16, 186-186.	3.5	4
35	Positive results for anifrolumab in phase III SLE trial. Nature Reviews Rheumatology, 2020, 16, 125-125.	3.5	4
36	Canakinumab relieves gout flares when treatment options are limited. Nature Reviews Rheumatology, 2012, 8, 369-369.	3.5	3

#	Article	IF	Citations
37	Granulocyte-macrophage colony-stimulating factor required for inflammatory and arthritic pain. Nature Reviews Rheumatology, 2012, 8, 499-499.	3.5	3
38	JAK inhibition with tofacitinib curbs RANKL-induced joint damage. Nature Reviews Rheumatology, 2012, 8, 564-564.	3.5	3
39	A new STING-associated monogenic autoinflammatory disease. Nature Reviews Rheumatology, 2014, 10, 512-512.	3.5	3
40	Dishing up functional human cartilage. Nature Reviews Rheumatology, 2014, 10, 321-321.	3.5	3
41	SSAT1 inhibition slows synovial fibroblast invasion. Nature Reviews Rheumatology, 2014, 10, 259-259.	3.5	3
42	Clues to the HLAâ€“RA connection from T-cell crossreactivity to vinculin and microorganisms. Nature Reviews Rheumatology, 2015, 11, 384-384.	3.5	3
43	Potent small molecule extinguishes the NLRP3 inflammasome. Nature Reviews Rheumatology, 2015, 11, 198-198.	3.5	3
44	IgG immune complexes directly regulate bone homeostasis. Nature Reviews Rheumatology, 2015, 11, 257-257.	3.5	3
45	PR3 on apoptotic cells promotes inflammation in GPA. Nature Reviews Rheumatology, 2015, 11, 683-683.	3.5	3
46	C5orf30 regulates severity of tissue destruction in RA. Nature Reviews Rheumatology, 2015, 11, 622-622.	3.5	3
47	Apoptotic cells induce immune memory. Nature Reviews Rheumatology, 2016, 12, 559-559.	3.5	3
48	Adalimumab drives Treg cell expansion via membrane TNF. Nature Reviews Rheumatology, 2016, 12, 438-438.	3.5	3
49	Cell-type-specific approach to TNF inhibition. Nature Reviews Rheumatology, 2016, 12, 194-194.	3.5	3
50	TFH cells link gut microbiota and arthritis. Nature Reviews Rheumatology, 2016, 12, 133-133.	3.5	3
51	Celecoxib reduces risk of ulcer bleeding. Nature Reviews Rheumatology, 2017, 13, 324-324.	3.5	3
52	Obesity skews markers of inflammation. Nature Reviews Rheumatology, 2017, 13, 323-323.	3.5	3
53	Anti-TNF agents go head-to-head. Nature Reviews Rheumatology, 2017, 13, 2-2.	3.5	3
54	IL-36 inhibition to treat OA. Nature Reviews Rheumatology, 2019, 15, 386-386.	3.5	3

#	Article	IF	Citations
55	New data emerging on outcomes for patients with COVID-19 and rheumatic diseases. Nature Reviews Rheumatology, 2020, 16, 407-407.	3.5	3
56	Abatacept no better than placebo for pSS. Nature Reviews Rheumatology, 2020, 16, 186-186.	3.5	3
57	ABCG2 SNP associated with early-onset gout. Nature Reviews Rheumatology, 2020, 16, 186-186.	3.5	3
58	Ustekinumab after anti-TNF failure: a step closer to the PSUMMIT of psoriatic arthritis therapy?. Nature Reviews Rheumatology, 2014, 10, 125-125.	3.5	2
59	A role for CXCR2 signalling in cartilage homeostasis. Nature Reviews Rheumatology, 2014, 10, 576-576.	3.5	2
60	Inflammasome-driven arthritis: a new model of RA?. Nature Reviews Rheumatology, 2014, 10, 445-445.	3.5	2
61	Metabolic changes modify Treg cell function. Nature Reviews Rheumatology, 2016, 12, 621-621.	3.5	2
62	Loss of immunoinhibitory checkpoint implicated in GCA. Nature Reviews Rheumatology, 2017, 13, 129-129.	3.5	2
63	Metabolic syndrome and risk of knee OA. Nature Reviews Rheumatology, 2017, 13, 257-257.	3.5	2
64	Anakinra effective for resistant FMF in RCT. Nature Reviews Rheumatology, 2017, 13, 2-2.	3.5	2
65	Biologics and risk of second malignant neoplasm. Nature Reviews Rheumatology, 2018, 14, 62-62.	3.5	2
66	Tofacitinib shows promise in PsA trials. Nature Reviews Rheumatology, 2018, 14, 4-4.	3.5	2
67	Subtype of JIA is genetically similar to adult RA. Nature Reviews Rheumatology, 2018, 14, 181-181.	3.5	2
68	Namilumab improves RA symptoms. Nature Reviews Rheumatology, 2019, 15, 318-318.	3.5	2
69	Burden of musculoskeletal diseases increasing. Nature Reviews Rheumatology, 2019, 15, 318-318.	3.5	2
70	First EULAR recommendations for SjÃ¶gren syndrome published. Nature Reviews Rheumatology, 2020, 16, 2-2.	3.5	2
71	Targeting adenosine in SSc. Nature Reviews Rheumatology, 2020, 16, 298-298.	3.5	2
72	OA chondrocytes made senescent by genomic DNA damage. Nature Reviews Rheumatology, 2012, 8, 502-502.	3.5	1

#	Article	IF	Citations
73	Evidence from animal studies supports the 'entheseal stress' hypothesis of ankylosing spondylitis. Nature Reviews Rheumatology, 2012, 8, 248-248.	3.5	1
74	Surgical options for hip OA: digging beneath the surface of implant survival. Nature Reviews Rheumatology, 2012, 8, 631-631.	3.5	1
75	Methotrexate and bridging glucocorticoids in early RA. Nature Reviews Rheumatology, 2014, 10, 698-698.	3.5	1
76	A NET of peril for endothelial cells in SLE?. Nature Reviews Rheumatology, 2014, 10, 195-195.	3.5	1
77	BiP peptides induce epitope-specific T-cell reactions in RA. Nature Reviews Rheumatology, 2015, 11, 259-259.	3.5	1
78	Glucosamineâ€“chondroitin combo improves knee OA pain. Nature Reviews Rheumatology, 2015, 11, 126-126.	3.5	1
79	Demethylation of IFN-regulated genes in SLE neutrophils. Nature Reviews Rheumatology, 2015, 11, 128-128.	3.5	1
80	Targeting epigenetic regulation of osteoclastogenesis to prevent bone loss. Nature Reviews Rheumatology, 2015, 11, 195-195.	3.5	1
81	Going upstream: peptidomimetics block shared-epitope signalling. Nature Reviews Rheumatology, 2015, 11, 320-320.	3.5	1
82	Blood vessel microenvironment sustains cell renewal in Dupuytren contracture nodules. Nature Reviews Rheumatology, 2015, 11, 444-444.	3.5	1
83	Autoantibodies to PDGFR are profibrotic in vivo. Nature Reviews Rheumatology, 2016, 12, 316-316.	3.5	1
84	Stroke risk increased after herpes zoster infection. Nature Reviews Rheumatology, 2016, 12, 622-622.	3.5	1
85	DNASE1L3 prevents anti-DNA responses. Nature Reviews Rheumatology, 2016, 12, 437-437.	3.5	1
86	A nose for cartilage repair. Nature Reviews Rheumatology, 2016, 12, 691-691.	3.5	1
87	Neutrophil microvesicles protect cartilage in arthritis. Nature Reviews Rheumatology, 2016, 12, 1-1.	3.5	1
88	Antifibrotic effects of PDE4 blockade?. Nature Reviews Rheumatology, 2017, 13, 198-198.	3.5	1
89	Short telomeres in gout linked with flares and CVD. Nature Reviews Rheumatology, 2017, 13, 324-324.	3.5	1
90	Evidence of gut-driven inflammation in new JIA. Nature Reviews Rheumatology, 2017, 13, 632-632.	3.5	1

#	Article	IF	Citations
91	Cytokines alter inflammatory responses via chromatin changes. Nature Reviews Rheumatology, 2017, 13, 569-569.	3.5	1
92	JAK-ing up inadequate RA therapy. Nature Reviews Rheumatology, 2017, 13, 513-513.	3.5	1
93	RA synovium harbours distinct fibroblast subsets. Nature Reviews Rheumatology, 2018, 14, 250-250.	3.5	1
94	Bystander-activated T cells contribute to Lyme arthritis. Nature Reviews Rheumatology, 2018, 14, 123-123.	3.5	1
95	Potassium channel regulates osteoclastogenesis. Nature Reviews Rheumatology, 2018, 14, 64-64.	3.5	1
96	Higher disease risk in children of women with RA. Nature Reviews Rheumatology, 2018, 14, 62-62.	3.5	1
97	Rituximab improves SLE disease activity. Nature Reviews Rheumatology, 2018, 14, 62-62.	3.5	1
98	TNF drives cryopyrinopathies in mice. Nature Reviews Rheumatology, 2018, 14, 63-63.	3.5	1
99	New insights into risk factors for GPA. Nature Reviews Rheumatology, 2018, 14, 248-248.	3.5	1
100	P. gingivalis exacerbates arthritis via gut barrier dysfunction. Nature Reviews Rheumatology, 2019, 15, 512-512.	3.5	1
101	Neuronal Fcî³ receptors mediate joint pain in arthritis. Nature Reviews Rheumatology, 2019, 15, 450-450.	3.5	1
102	Stratifying SjÃ¶gren syndrome into symptom-based subgroups. Nature Reviews Rheumatology, 2019, 15, 698-698.	3.5	1
103	Is Kawasaki disease a form of IgA vasculitis?. Nature Reviews Rheumatology, 2019, 15, 636-636.	3.5	1
104	Rare variants in SLE risk genes drive disease. Nature Reviews Rheumatology, 2019, 15, 384-384.	3.5	1
105	Hospitalization for infection on the rise in gout. Nature Reviews Rheumatology, 2020, 16, 296-296.	3.5	1
106	Pro-senescence therapy reduces joint inflammation. Nature Reviews Rheumatology, 2020, 16, 249-249.	3.5	1
107	TYK2 inhibition halts SpA. Nature Reviews Rheumatology, 2020, 16, 248-248.	3.5	1
108	EULAR updates its RA management recommendations. Nature Reviews Rheumatology, 2020, 16, 128-128.	3.5	1

#	Article	IF	Citations
109	Spirochaete remnants could explain antibiotic-refractory Lyme arthritis. Nature Reviews Rheumatology, 2012, 8, 440-440.	3.5	0
110	Bare bones of glucocorticoid effects on metabolism. Nature Reviews Rheumatology, 2012, 8, 694-694.	3.5	0
111	GO-FURTHER with intravenous golimumab for active RA. Nature Reviews Rheumatology, 2012, 8, 439-439.	3.5	0
112	Does ultrasonography reliably detect bone erosion in RA metacarpophalangeal joints?. Nature Reviews Rheumatology, 2012, 8, 367-367.	3.5	0
113	A new path to treating arthritis?. Nature Reviews Rheumatology, 2013, 9, 2-2.	3.5	0
114	New insights into functional effects of the shared epitope. Nature Reviews Rheumatology, 2013, 9, 3-3.	3.5	0
115	A new therapeutic approach for APS?. Nature Reviews Rheumatology, 2014, 10, 259-259.	3.5	0
116	Does metal-on-metal hip resurfacing confer a survival advantage over total hip replacement?. Nature Reviews Rheumatology, 2014, 10, 65-65.	3.5	0
117	Does norepinephrine influence cartilage repair?. Nature Reviews Rheumatology, 2014, 10, 383-383.	3.5	0
118	Immune surveillance stops joint-invading Borrelia in mice. Nature Reviews Rheumatology, 2014, 10, 638-638.	3.5	0
119	Depleting plasmacytoid dendritic cells: a new therapeutic approach in SLE?. Nature Reviews Rheumatology, 2014, 10, 573-573.	3.5	0
120	Manipulating the FLS 'proteoglycan switch' could offer a new approach to RA therapy. Nature Reviews Rheumatology, 2015, 11, 381-381.	3.5	0
121	Meta-analysis reveals novel overlap in genetic aetiologies of paediatric autoimmune disorders. Nature Reviews Rheumatology, 2015, 11, 561-561.	3.5	0
122	Local versus systemic treatment for tenosynovitis. Nature Reviews Rheumatology, 2016, 12, 622-622.	3.5	0
123	Joint resurfacing possibilities loom large. Nature Reviews Rheumatology, 2016, 12, 497-497.	3.5	0
124	Muscle pathology helps predict JDM outcomes. Nature Reviews Rheumatology, 2016, 12, 375-375.	3.5	0
125	An evolving autoantibody response in RA?. Nature Reviews Rheumatology, 2016, 12, 193-193.	3.5	0
126	Systemic JIA genetically distinct. Nature Reviews Rheumatology, 2017, 13, 65-65.	3.5	0

#	Article	IF	Citations
127	Hit the DEK!. Nature Reviews Rheumatology, 2017, 13, 196-197.	3.5	0
128	IL-37 fights inflammation-induced fatigue. Nature Reviews Rheumatology, 2017, 13, 258-258.	3.5	0
129	Multi-pronged approach uncovers sJIA mechanisms. Nature Reviews Rheumatology, 2017, 13, 631-631.	3.5	0
130	Infection risk after switching biologics. Nature Reviews Rheumatology, 2017, 13, 570-570.	3.5	0
131	Reinforcing 'treat to target' for SpA. Nature Reviews Rheumatology, 2017, 13, 514-514.	3.5	0
132	Ultrasonography in GCA assessment. Nature Reviews Rheumatology, 2017, 13, 695-695.	3.5	0
133	Caution needed in use of gabapentinoids for LBP. Nature Reviews Rheumatology, 2017, 13, 570-570.	3.5	0
134	Intravenous golimumab effective for PsA. Nature Reviews Rheumatology, 2017, 13, 570-570.	3.5	0
135	Hyperactive macrophages link heart and joint disease. Nature Reviews Rheumatology, 2018, 14, 182-182.	3.5	0
136	T cells in blood mark SjÃ¶gren syndrome activity. Nature Reviews Rheumatology, 2018, 14, 122-122.	3.5	0
137	Methotrexate for chronic chikungunya arthritis?. Nature Reviews Rheumatology, 2018, 14, 122-122.	3.5	0
138	Long-term mavrilimumab safe and effective. Nature Reviews Rheumatology, 2018, 14, 122-122.	3.5	0
139	Effects of certolizumab pegol sustained at 4 years. Nature Reviews Rheumatology, 2018, 14, 122-122.	3.5	0
140	Hydroxychloroquine no HERO for hand OA. Nature Reviews Rheumatology, 2018, 14, 248-248.	3.5	0
141	Incidence of flare is increased in pregnancy. Nature Reviews Rheumatology, 2018, 14, 248-248.	3.5	0
142	Obesity hampers effects of anti-TNF agents. Nature Reviews Rheumatology, 2018, 14, 320-320.	3.5	0
143	Denosumab shows promise for GIOP. Nature Reviews Rheumatology, 2018, 14, 320-320.	3.5	0
144	Triple therapy boosts survival in catastrophic APS. Nature Reviews Rheumatology, 2018, 14, 320-320.	3.5	0

#	Article	IF	Citations
145	Flares not linked to ultrasound findings in JIA. Nature Reviews Rheumatology, 2018, 14, 320-320.	3.5	0
146	Targeting the CRPâ€“HIF1Î± axis in RA improves response to leflunomide. Nature Reviews Rheumatology, 2019, 15, 699-699.	3.5	0
147	Vaccination guidance updated. Nature Reviews Rheumatology, 2019, 15, 574-574.	3.5	0
148	Improving how we talk about gout. Nature Reviews Rheumatology, 2019, 15, 635-635.	3.5	0
149	A new model to study BAFF-independent SLE. Nature Reviews Rheumatology, 2019, 15, 636-636.	3.5	0
150	Complement activation precedes classifiable SLE. Nature Reviews Rheumatology, 2019, 15, 636-636.	3.5	0
151	Taking ABAT to OA. Nature Reviews Rheumatology, 2019, 15, 700-700.	3.5	0
152	LLDAS is an attainable SLE treatment target. Nature Reviews Rheumatology, 2019, 15, 636-636.	3.5	0
153	New insights into myositis genetics. Nature Reviews Rheumatology, 2019, 15, 451-451.	3.5	0
154	Engineered fusion protein disrupts CD40 signalling. Nature Reviews Rheumatology, 2019, 15, 385-385.	3.5	0
155	Daily atorvastatin safe for patients with RA. Nature Reviews Rheumatology, 2019, 15, 318-318.	3.5	0
156	TIGIT-Ig shows therapeutic potential in SLE. Nature Reviews Rheumatology, 2019, 15, 318-318.	3.5	0
157	Inhibit tankyrase to preserve OA cartilage?. Nature Reviews Rheumatology, 2020, 16, 3-3.	3.5	0
158	New autoinflammatory disease caused by non-cleavable RIPK1 variants. Nature Reviews Rheumatology, 2020, 16, 61-61.	3.5	0
159	Physical therapy better than steroids for knee OA. Nature Reviews Rheumatology, 2020, 16, 296-296.	3.5	0
160	Early referral matters for RA outcomes. Nature Reviews Rheumatology, 2020, 16, 350-350.	3.5	0
161	Tanezumab improves difficult-to-treat OA. Nature Reviews Rheumatology, 2020, 16, 296-296.	3.5	0
162	Anti-TNF response falls short in real-world cohort. Nature Reviews Rheumatology, 2020, 16, 350-350.	3.5	0

#	Article	IF	Citations
163	MMF comparable to cyclophosphamide in AAV. Nature Reviews Rheumatology, 2020, 16, 350-350.	3.5	0
164	Increased risk of infection-related death in SLE. Nature Reviews Rheumatology, 2020, 16, 350-350.	3.5	0
165	GCA relapse common in ustekinumab trial. Nature Reviews Rheumatology, 2020, 16, 296-296.	3.5	0
166	Plasma exchange fails to improve outcomes for ANCA-associated vasculitis. Nature Reviews Rheumatology, 2020, 16, 185-185.	3.5	0
167	Gene expression profiles in muscle differ in myositis subtypes. Nature Reviews Rheumatology, 2020, 16, 409-409.	3.5	0
168	Leflunomide plus glucocorticoids for IgG4-RD. Nature Reviews Rheumatology, 2020, 16, 186-186.	3.5	0